AI Article Synopsis
- The study explores the use of tumor-associated antigens (TAAs) as early diagnostic tools for hepatocellular carcinoma (HCC), specifically focusing on Hispanic patients who may have unique risk factors.
- Researchers identified four significant anti-TAA autoantibodies—DNMT3A, p16, Hsp60, and HSPA5—that showed higher levels in the serum of Hispanic HCC patients, with a combined testing approach increasing diagnostic sensitivity to 75%.
- Findings suggest that these autoantibodies, particularly DNMT3A and HSP60, could serve as valuable diagnostic biomarkers specifically for Hispanic HCC patients, indicating a potentially distinct profile in this demographic.
Article Abstract
Background: Tumor-associated antigens (TAAs) have been investigated for many years as potential early diagnosis tools, especially for hepatocellular carcinoma (HCC). Nonetheless, very few studies have focused on the Hispanic HCC group that may be associated with distinct etiological risk factors. In the present study, we investigated novel anti-TAA autoantibodies as diagnostic biomarkers for Hispanic HCC patients.
Methods: Novel TAA targets were identified by the serological proteome analysis (SERPA) and from differentially expressed HCC driver genes via bioinformatics. The autoantibody levels were validated by enzyme-linked immunosorbent assay (ELISA).
Results: Among 19 potential TAA targets, 4 anti-TAA autoantibodies were investigated as potential diagnostic biomarkers with significantly high levels in Hispanic HCC sera, including DNA methyltransferase 3A (DNMT3A), p16, Hear shock protein 60 (Hsp60), and Heat shock protein A5 (HSPA5). The area under the ROC curve (AUC) value of the single autoantibodies varies from 0.7505 to 0.8885. After combining all 4 autoantibodies, the sensitivity of the autoantibody panel increased to 75% compared to the single one with the highest value of 45.8%. In a separate analysis of the Asian cohort, autoantibodies against HSPA5 and p16 showed significantly elevated levels in HCC compared to normal healthy controls, but not for DNMT3A or HSP60.
Conclusion: Anti-DNMT3A, p16, HSPA5, and HSP60 autoantibodies have the potential to be diagnostic biomarkers for Hispanic HCC patients, of which DNMT3A and HSP60 might be exclusive for Hispanic HCC diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600682 | PMC |
| http://dx.doi.org/10.3390/cells11203227 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment and Survival Disparities in Asian Americans With Hepatocellular Carcinoma: The Need to Disaggregate a Diverse Cohort.
J Clin Gastroenterol
October 2024
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY.
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in the United States and globally. The Asian American, Native Hawaiian, and Pacific Islander (AANHPI) population has often been studied as one homogenous cohort despite its heterogeneity. We aim to understand differences in treatment modality and mortality among AANHPI patients with early-stage HCC.
View Article and Find Full Text PDFAccess to Care and the Hispanic Paradox Among Hispanic Patients with Hepatocellular Carcinoma.
Clin Res Hepatol Gastroenterol
December 2024
University of Illinois Chicago, Chicago, IL. Electronic address:
Purpose: Despite the disproportionate impact of hepatocellular carcinoma (HCC) on Hispanic patients, reported outcomes are limited, particularly among subpopulations. Our study aimed to evaluate outcomes in access to care and survival among racial and ethnic Hispanic subpopulations.
Methods: The National Cancer Database was then utilized to identify patients diagnosed with HCC between 2004 and 2020.
Impact of racial, ethnic, and socioeconomic disparities on presentation and survival of HCC: A multicenter study.
Hepatol Commun
November 2024
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Background: Racial and ethnic disparities have been reported for HCC prognosis, although few studies fully account for clinically important factors and social determinants of health, including neighborhood socioeconomic status.
Methods: We conducted a retrospective multicenter cohort study of patients newly diagnosed with HCC from January 2010 through August 2018 at 4 large health systems in the United States. We used multivariable logistic regression and cause-specific Cox proportional hazard models to identify factors associated with early-stage HCC presentation and overall survival.
Objective: We aimed to systematically investigate the associations between racial discrimination and various health outcomes and to evaluate the certainty of evidence from existing meta-analyses of observational studies.
Method: We systemically searched the associations between racial discrimination and health outcomes for PubMed/MEDLINE, Embase, WoS, and Google Scholar up until January 31, 2024. Notably, the included studies were predominantly conducted in the United States and Europe, limiting the generalizability of our findings to a global context.
Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors.
Cancer Epidemiol Biomarkers Prev
December 2024
Stanford University, Palo Alto, California, United States.
Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!